Ticagrelor reduces in-stent thrombosis in patients with acute coronary syndromes

Original title: Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: An analysis from the prospective randomized PLATO trial. Reference: Steg PG et al. Circulation. 2013; Epub ahead of print

The PLATO study randomized 18624 patients with acute coronary syndrome to receive ticagrelor   (180 mg loading dose followed by 90 mg twice daily ) or clopidogrel ( 300 or 600 mg loading dose followed by 75 mg per day ) . The results of this study published in NEJM showed a reduction in the composite of cardiac death , heart attack and stroke ( primary end point ) .

This paperwork reported the results of 61% of patients in the PLATO (n = 11289 ) who received angioplasty with stent either prior to study ( n = 1404 ) or during the same ( n = 9885 ) . At 12 months the definitive in-stent thrombosis was significantly lower with ticagrelor compared with clopidogrel ( 1.37 % versus 1.93 % , HR 0.67 , CI 0.5-0.9 , p = 0.0091 ) .The result was similar when considering all thrombosis together (definite, probable and possible) with 2.94 % for ticagrelor branch versus  3.77 % for the clopidogrel branch (HR 0.77, CI 0.62 to 0.95 , P = 0.013 ) .

The definitive thrombosis rate was consistently lower with ticagrelor beyond the type of acute coronary syndrome , diabetes , drug-eluting stent use , use of glycoprotein IIbIIIa , etc). Out of 147 cases with definite thrombosis furthermost  were subacute (58.5 % ) , followed by late thrombosis (24.5 %) and acute ( 17 % ) .Ticagrelor decreased subacute thrombosis and late but not acute ( within 24 hours).Patients with stent thrombosis showed a higher risk of bleeding and death from all causes after the event than they had before.

Conclusion: 

Ticagrelor compared with clopidogrel reduces the incidence of stent thrombosis in patients with acute coronary syndromes , with a benefit consisting of a wide range of patients , stents and treatment characteristics .

Editorial Comment:

Although the absolute difference in stent thrombosis is small, this complication is associated with a high mortality rate and myocardial infarction (confirmed in this study once more).

SOLACI.ORG

More articles by this author

Spontaneous Left Main Dissection: Clinical Characteristics, management and Outcomes

Courtesy of Dr. Juan Manuel Pérez. Spontaneous left main dissection in an uncommon, and potentially life-threatening, cause of acute MI. The aim of this study,...

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACURATE Neo2 Underexpansion: Prevalence and Clinical Implications

While transcatheter aortic valve replacement (TAVR) provides durable clinical benefits across a wide range of patients, technical challenges remain that may affect long-term outcomes....

Spontaneous Left Main Dissection: Clinical Characteristics, management and Outcomes

Courtesy of Dr. Juan Manuel Pérez. Spontaneous left main dissection in an uncommon, and potentially life-threatening, cause of acute MI. The aim of this study,...

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...